Does aggregation dominate for cagrilintide held at minus 80 °C?

Setup, so nobody has to ask: aggregation · cagrilintide · minus 80 °C.

I keep seeing this stated as a fact with no explanation attached, and unexplained facts make me suspicious.

My background is quantitative but not chemical, so I can follow an equation more easily than a hand-wave.

Why does this happen, and what would falsify the usual explanation?

At minus 80 °C the question is which route is fastest, not whether aggregation happens — and the routes do not share an activation energy, so their ranking changes with temperature. minus 80 °C is 85 kelvin below a refrigerator, and below the glass transition of a lyophilised cake the ten-degree rule of thumb stops applying at all — solid-state chemistry is not slow liquid chemistry, it is a different regime, and the failure modes that survive it are mechanical rather than chemical. That multiplier is an average over every route at once, which is exactly why it cannot tell you which one wins. Molecules associate without any covalent change, so the mass is unchanged and a reversed-phase run — which is performed in organic solvent — mostly dissolves the evidence before it can be measured. So the way to answer it for your vial is to pick the method that sees aggregation specifically and run it against a control held cold, rather than to infer a mechanism from a purity number that averages all of them.

The honest answer is that most reported "degradation" is adsorption and dilution error rather than chemistry.

Oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Metal-catalysed oxidation of methionine is documented across peptide and protein formulations and is why chelators appear in some formulations.

At dilute concentrations, suspect adsorption before you suspect chemistry.

The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

In practice, hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Sequence decides which pathways are even available. Check the residues.

Answering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

A mass spectrum resolves most of this: minus eighteen is dehydration or succinimide, plus one is deamidation, plus sixteen is oxidation, and an unchanged mass with a shifted retention time is an isomer.

Apparent loss in a dilute preparation is usually adsorption rather than degradation and is worth ruling out first.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

The caveat is that none of these pathways can be seen by looking at a vial, and a clear solution can be substantially degraded.

Cold, dry, dark, still. Those four words cover most of the mitigation.

edited 23 Oct 2025 by plate_count_9k — added the placebo-arm figures